Ironwood Pharmaceuticals

Linaclotide (Linzess) provides significant relief for functional constipation in children with neurodevelopmental disorders, according to a posthoc analysis presented at NASPGHAN 2024. The analysis showed similar benefits and safety profiles compared to the overall trial population, with high compliance rates.

Calluna Pharma appoints Mark Gaffney as CEO and Mark Altmeyer as Chair of the Board. Gaffney brings 20+ years of biotech experience, previously at Oxular and Vedere Bio. Altmeyer, with extensive pharma and biotech leadership, currently chairs AM-Pharma and serves on several boards. Calluna's lead candidate, CAL101, is on track to complete Phase 1 this year.

Calluna Pharma appoints Mark Gaffney as CEO; Gaffney brings 20+ years of experience in biotech, previously CEO of Oxular Limited and COO at Vedere Bio (acquired by Novartis). Gaffney will lead Calluna's strategy as CAL101 completes Phase 1 this year.

Tulisokibart, an anti-TL1A monoclonal antibody, outperformed placebo in inducing clinical remission at week 12 in moderate to severe ulcerative colitis, according to the ARTEMIS-UC trial. The study incorporated a predictive biomarker for response, showing significant clinical remission, endoscopic improvement, and clinical response in patients on tulisokibart compared to placebo. A phase 3 program is planned to confirm these results.

Inspire Investing LLC increased its stake in Ironwood Pharmaceuticals by 34.1% during Q2, owning 54,677 shares worth $356,000. Several hedge funds also adjusted their positions, and insider Minardo John sold 9,910 shares at $4.27 each. Ironwood Pharmaceuticals opened at $4.30 on Friday, with a market cap of $673.07 million. Analysts have issued mixed ratings, resulting in a consensus 'Moderate Buy' rating with a target price of $13.57. The company focuses on GI product development and commercialization, notably linaclotide.